Your session is about to expire
← Back to Search
Other
AB-205 for Lymphoma (E-CELERATE Trial)
Phase 3
Waitlist Available
Research Sponsored by Angiocrine Bioscience
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 21 days
Awards & highlights
E-CELERATE Trial Summary
This trial is testing a drug to see if it can prevent or reduce severe complications from high-dose chemotherapy in lymphoma patients.
Who is the study for?
Adults over 40 with Hodgkin or non-Hodgkin lymphoma, in partial or complete remission, can join this trial. They must be fit enough for high-dose chemotherapy and stem cell transplant, have good heart and lung function, normal liver enzymes, a creatinine clearance of at least 30 ml/min, and not exceed a certain weight limit. Participants must agree to use two forms of contraception if they are sexually active.Check my eligibility
What is being tested?
The study tests whether AB-205 can prevent or lessen severe complications from high-dose chemotherapy in lymphoma patients undergoing stem cell transplants compared to a placebo. All participants will receive standard care alongside the test drug or placebo.See study design
What are the potential side effects?
Potential side effects aren't specified here but may include reactions related to immune system suppression due to chemotherapy and transplantation procedures such as infections, bleeding issues, nausea, fatigue among others.
E-CELERATE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 21 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~21 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The absence of oral/GI severe regimen related toxicities (oral/GI SRRT).
Secondary outcome measures
Duration of febrile neutropenia
Duration of oral/GI SRRT
Symptom burden per MD Anderson Symptom Inventory (MDASI)
+1 moreE-CELERATE Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: AB-205 plus standard-of-care preventive and supportive therapies.Experimental Treatment1 Intervention
Group II: Placebo plus standard-of-care preventive and supportive therapies.Placebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AB-205
2019
Completed Phase 1
~50
Find a Location
Who is running the clinical trial?
Angiocrine BioscienceLead Sponsor
4 Previous Clinical Trials
84 Total Patients Enrolled
California Institute for Regenerative Medicine (CIRM)OTHER
63 Previous Clinical Trials
3,018 Total Patients Enrolled
Paul Finnegan, MDStudy DirectorAngiocrine Bioscience, Inc.
2 Previous Clinical Trials
52 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: AB-205 plus standard-of-care preventive and supportive therapies.
- Group 2: Placebo plus standard-of-care preventive and supportive therapies.
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this clinical trial accessible to patients in different parts of the city?
"University of Iowa Hospitals & Clinics, University of Miami - Sylvester Comprehensive Cancer Center, and Weill Cornell Medical College/New york Presbyterian Hospital are all participating in this trial and recruiting patients. There are a total of 26 sites taking part in this study."
Answered by AI
Could you please elaborate on the dangers associated with AB-205?
"AB-205 has received a score of 3 from our analysts at Power. This is due to the fact that AB-205 is in Phase 3 clinical trials, thus meaning that multiple rounds of safety data have been collected in addition to some efficacy data."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger